HEALTH-RELATED QUALITY OF LIFE WITH GUSELKUMAB INDUCTION AND MAINTENANCE THERAPY AS MEASURED BY PROMIS-29: RESULTS THROUGH WEEK 48 OF PHASE 2 GALAXI 1 STUDY

Geert R. D'Haens  1     Bruce E. Sands  2     Remo Panaccione  3     Chenglong Han  4     Susana Gonzalez  5     Kathleen Weisel  5     Mary Ellen Frustuaci  5     Zijiang Yang  5     Aparna Sahoo  5     Anita Afzali  6     Jane Andrews  7     Silvio Danese  8     Tadakazu Hisamatsu  9     Brian G. Feagan  10     Julian Panés  11     Walter Reinisch  12     William Sandborn  13     David T. Rubin  14    
1 Amsterdam UMC, Amsterdam, Netherlands
2 Icahn School of Medicine at Mount Sinai, New York, United States
3 University of Calgary, Calgary, Canada
4 Janssen Global Services, LLC, Malvern, United States
5 Janssen Research & Development, LLC, Spring House
6 The Ohio State University Wexner Medical Center, Columbus, United States
7 Royal Adelaide Hospital & University of Adelaide, Adelaide
8 IRCCS Ospedale San Raffaele and University Vita-Salute San Raffaele, Milan, Italy
9 Kyorin University, Tokyo, Japan
10 Alimentiv Inc., London, Canada
11 Hospital Clínic Barcelona, Barcelona, Spain
12 Medical University of Vienna, Vienna, Austria
13 University of California San Diego, San Diego, United States
14 University of Chicago Medicine, Chicago, United States

Session
IBD (Posters)

Conference
UEG Week 2022

Citation
United European Gastroenterology Journal 2022; 10 (Supplement 8)


Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Social Sharing